<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3829">
  <stage>Registered</stage>
  <submitdate>26/07/2012</submitdate>
  <approvaldate>26/07/2012</approvaldate>
  <nctid>NCT01652482</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)</studytitle>
    <scientifictitle>A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-005547-27</secondaryid>
    <secondaryid>GO28074</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - 5-fluorouracil
Treatment: drugs - Cetuximab
Treatment: drugs - Irinotecan
Treatment: drugs - Leucovorin
Treatment: drugs - MEHD7945A

Active Comparator: FOLFIRI + Cetuximab - 

Experimental: FOLFIRI + MEHD7945A - 


Treatment: drugs: 5-fluorouracil
Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter [mg/m^2] administered as intravenous bolus and then 5-FU 2400 mg/m^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Treatment: drugs: Cetuximab
Cetuximab 400 mg/m^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.

Treatment: drugs: Irinotecan
Standard Irinotecan chemotherapy (180 milligram per square meter [mg/m^2] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Treatment: drugs: Leucovorin
Standard Leucovorin chemotherapy (400 mg/m^2 [racemic form] or 200 mg/m^2 [L-isomer form] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.

Treatment: drugs: MEHD7945A
MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free Survival (PFS) According to Modified RECIST v1.1 Criteria</outcome>
      <timepoint>approximately 2 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Concentration of 5-Fluorouracil</outcome>
      <timepoint>Pre-dose, 1 hour and after end of infusion on Day 1 Cycles 1-4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Concentration of Irinotecan</outcome>
      <timepoint>Pre-dose, 1 hour and after end of infusion on Day 1 Cycles 1-4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Anti-MEHD7945A Antibodies</outcome>
      <timepoint>Pre-dose on Day 1 Cycles 1, 4, and 8; treatment completion visit (up to approximately 2 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Objective Response According to Modified RECIST v1.1 Criteria</outcome>
      <timepoint>approximately 2 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Objective Response According to Modified RECIST v1.1 Criteria</outcome>
      <timepoint>approximately 2 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>approximately 2 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Adverse Events</outcome>
      <timepoint>approximately 2 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Observed Serum Concentration (Cmax) of MEHD7945A</outcome>
      <timepoint>Pre-dose and 30 minutes after end of infusion on Day 1 Cycles 1-4, Cycle 8 and at treatment completion (up to approximately 2 year)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum Observed Serum Concentration (Cmin) of MEHD7945A</outcome>
      <timepoint>Pre-dose on Day 1 Cycles 1-4, Cycle 8 and at treatment completion (up to approximately 2 year)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically or cytologically confirmed adenocarcinoma of the colon and/or rectum,
             with KRAS wild-type status

          -  Progressive disease on or after first-line oxaliplatin-containing regimen for mCRC;
             participants must have received oxaliplatin-containing chemotherapy for greater than
             or equal to (&gt;/=) 3 months; no more than one prior chemotherapy regimen for metastatic
             disease is allowed

          -  Measurable disease per modified Response Evaluation Criteria in Solid Tumors Version
             1.1 (RECIST v1.1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic and end-organ function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior treatment with irinotecan

          -  Prior treatment with an investigational or approved human epidermal growth factor
             receptor (HER)-targeted agent

          -  Last anti-tumor therapy within 4 weeks prior to Cycle 1, Day 1

          -  Leptomeningeal disease as the only manifestation of the current malignancy

          -  Active infection requiring intravenous antibiotics

          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory
             drugs

          -  Current severe, uncontrolled systemic disease

          -  Known human immunodeficiency virus (HIV) infection

          -  Untreated/active central nervous system metastases (progressing or requiring
             anticonvulsants or corticosteroids for symptomatic control)

          -  Pregnant or lactating women

          -  Malignancies other than colorectal cancer within 5 years prior to randomization,
             except for adequately treated basal or squamous cell skin cancer and carcinoma in situ
             of the cervix</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>135</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital> - Darlinghurst</hospital>
    <hospital> - New Lambton Heights</hospital>
    <hospital> - St. Leonards</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Waratah</hospital>
    <hospital> - Wollongong</hospital>
    <hospital> - Herston</hospital>
    <hospital> - Southport</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Frankston</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2217 - Sydney</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4215 - Southport</postcode>
    <postcode>5041 - Adelaide</postcode>
    <postcode>3199 - Frankston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Haine-Saint-Paul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liège</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Stuttgart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Trier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Aberdeen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wirral</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label, randomized, multicenter, Phase 2 study will evaluate the safety and efficacy
      of MEHD7945A when combined with FOLFIRI (folinic acid [leucovorin], 5-fluorouracil [5-FU],
      and irinotecan) chemotherapy as compared to cetuximab plus FOLFIRI in participants with
      Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type mCRC who have progressed after
      first-line oxaliplatin-containing chemotherapy for metastatic disease. Participants will be
      randomized to receive FOLFIRI chemotherapy plus either MEHD7945A or cetuximab. Anticipated
      time on study treatment is until disease progression or unacceptable toxicity occurs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01652482</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Genentech, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>